This article is more than 5 years old. Information may no longer be current.
LensAR issued patent for laser treatment of cataract and presbyopia
Click Here to Manage Email Alerts
WINTER PARK, Fla. — LensAR has been issued a foundational patent for the use of laser technology in cataract and presbyopia treatment, the company announced in a press release.
U.S. patent No. 7,655,002 covers intellectual property related to laser technology being applied to increase the flexibility of the crystalline lens to restore accommodation and facilitate lens removal, the release said.
LensAR is the only company worldwide that is clinically evaluating laser treatment of the crystalline lens for presbyopia in human subjects, the release said.
"Intellectual property is the foundation of LensAR," Randy Frey, LensAR founder and CEO, said in the release. "We believe this issued patent will be the first of many in the area of laser treatment of the ocular lens. While we appreciate that a significant amount of development work, along with [U.S. Food and Drug Administration] approval, is still required to bring our LensAR Laser System to the market, we are fully committed to realizing our goal of ultimately enabling such valuable indications as capsulotomy, fragmentation, astigmatic and other corneal incisions for cataract surgery, as well as presbyopia treatment, all within one proprietary laser platform."
An initial feasibility study on laser treatment of the crystalline lens in human subjects is being conducted in Mexico and the Philippines. Earlier primate studies produced the safety profile that enabled the initiation of human clinical trials, the release said.
"It is important to note that the LensAR system was initially designed to correct presbyopia, and early clinical data established that it not only softened the lens but also showed the potential to restore its natural flexibility and accommodative power," Ronald R. Krueger, MD, a co-founder of LensAR, said.
Follow OSNSuperSite.com
on Twitter.